Product How it works Pricing Blog FAQ About Contact
Compass Therapeutics

Compass Therapeutics (NASDAQ: CMPX) net income

Compass Therapeutics reported a net loss of $66.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $49.4m. Earnings per share were −$0.42.

Compass Therapeutics's best year of the last 7 was fiscal 2020. It reported a loss in 7 of those 7 years.

Net income, in millions of US dollars-34.72019-29.52020-82.22021-39.22022-42.52023-49.42024-66.52025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$66.5m——−$0.42
2024−$49.4m—−5,808.8%−$0.36
2023−$42.5m——−$0.33
2022−$39.2m——−$0.37
2021−$82.2m——−$1.31
2020−$29.5m———
2019−$34.7m———

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Compass Therapeutics net income compared with its sector

By net income for its latest fiscal year, Compass Therapeutics ranks 287th of the 501 US health care companies with a page on Celsmar.

RankCompanyNet incomeNet margin
285thArcturus Therapeutics−$65.8m−80.2%
286thTarsus Pharmaceuticals−$66.4m−14.7%
287thCompass Therapeutics−$66.5m—
288thCytek Biosciences−$66.5m−33.0%
289thOcugen−$67.8m−1,537.4%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Compass Therapeutics

How much did Compass Therapeutics earn in fiscal 2025?
Compass Therapeutics reported a net loss of $66.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $49.4m.
What are the earnings per share of Compass Therapeutics?
They were −$0.42 in fiscal 2025, compared with −$0.36 in fiscal 2024.
Where does Compass Therapeutics rank in its sector by net income?
It ranks 287th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Compass Therapeutics come from?
From the annual report (Form 10-K) that Compass Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Compass Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Compass Therapeutics: the Compass Therapeutics page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.